Lung function and symptom improvement with fluticasone propionate/salmeterol and ipratropium bromide/albuterol in COPD: response by beta-agonist reversibility
ER Bleecker, A Emmett, G Crater, K Knobil… - Pulmonary pharmacology …, 2008 - Elsevier
This retrospective analysis of data from two multi-center, randomized, double-blind, parallel
group studies compared the efficacy of fluticasone propionate/salmeterol (FSC) 250/50mcg
twice daily with ipratropium bromide/albuterol (IB/ALB) 36/206 mcg four times daily in
albuterol-reversible (n= 320 [44%]) and non-reversible (n= 399 [56%]) patients with COPD.
In reversible and non-reversible patients, both treatments significantly increased FEV1AUC0–
6h from baseline and the magnitude of improvement was larger in reversible patients. FSC …
group studies compared the efficacy of fluticasone propionate/salmeterol (FSC) 250/50mcg
twice daily with ipratropium bromide/albuterol (IB/ALB) 36/206 mcg four times daily in
albuterol-reversible (n= 320 [44%]) and non-reversible (n= 399 [56%]) patients with COPD.
In reversible and non-reversible patients, both treatments significantly increased FEV1AUC0–
6h from baseline and the magnitude of improvement was larger in reversible patients. FSC …
以上显示的是最相近的搜索结果。 查看全部搜索结果